Abstract
The aim of this study is to review the experience of the clonidine suppression test in a regional endocrine centre and to compare the diagnostic sensitivity and specificity using various previous published criteria. The design used is retrospective study. The subjects include 56 patients in whom clonidine suppression tests had been performed from 1995 to 2000: 15 with phaeochromocytoma and 41 patients in whom the diagnosis was excluded using a combination of biochemical testing, abdominal computed tomography scanning and clinical follow-up. Plasma catecholamines were measured by high pressure liquid chromatography on basal samples and at hourly intervals for 3 h after the administration of clonidine 300 μg orally and the following diagnostic criteria were applied: plasma noradrenaline+adrenaline>2.96 nmol l–1 at 3 h post-clonidine or a baseline plasma adrenaline plus noradrenaline>11.82 nmol l–1; plasma noradrenaline>2.96 nmol l–1 at 3 h post-clonidine and plasma noradrenaline>2.96 nmol l–1 and <50% fall in noradrenaline at 3 h post-clonidine. The results obtained is that mean plasma noradrenaline plus adrenaline fell across the test in 40/41 patients in the non-phaeochromocytoma patients and was lowest at 3 h (basal 2.28±0.14 vs 1.36±0.11 nmol l–1, P<0.001). In the phaeochromocytoma group, clonidine had a variable effect on adrenaline plus noradrenaline levels with increases in 7/15. Using an abnormal result as a 3 h level of noradrenaline plus adrenaline>2.96 mmol l–1 gave a sensitivity of 93% and specificity of 95%. When a 3 h noradrenaline>2.96 mmol l–1 was used, sensitivity was 87% and specificity 95%. Using the former criteria, noradrenaline plus adrenaline>2.96 mmol l–1, 1/15 in the phaeochromocytoma group had a normal result after clonidine suppression testing. Two of 41 in the non-phaeochromocytoma group had a false-positive result. Under carefully controlled conditions, the clonidine suppression test is well tolerated, safe and accurate for use in the investigation of patients with suspected phaeochromocytoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ilias I, Pacak K . Current approaches and recommended algorithm for the diagnostic localization of phaeochromocytoma. J Clin Endocrinol Metab 2004; 89: 479–491.
Manger WM . In search of pheochromocytomas. J Clin Endocrinol Metab 2003; 88: 4080–4082.
Manger WM, Gifford Jr RW . Clinical and Experimental Pheochromocytoma. Blackwell Science: Cambridge, MA, 1996.
Manger WM, Gifford Jr RW . Phaeochromocytoma. J Clin Hypertens 2002; 4: 62–72.
Lenders JW, Eisenhofer G, Mannelli I, Pacak K . Phaeochromocytoma. Lancet 2005; 366: 665–675.
Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88: 2656–2666.
Lenz T, Ross A, Schumm-Draeger P, Schulte KL, Geiger H . Clonidine suppression test revisited. Blood Press 1998; 7: 153–159.
Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford Jr RW . Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981; 305: 623–626.
Bravo EL, Gifford RW . Phaeochromocytoma: diagnosis, localization and management. N Engl J Med 1984; 311: 1298–1303.
Manger WM . Phaeochromocytoma: clinical experience and overview. Curr Probl Cancer 1985; 9: 1–89.
Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL et al. Simultaneous liquid- chromographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986; 32: 2030–2033.
Lenders JWM, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin IJ . Determination of plasma metanephrines by liquid chromatography with electrochemical detection. Clin Chem 1993; 39: 97–103.
Grossman E, Goldstein D, Hoffman A, Keiser HR . Glucagon and clonidine testing in the diagnosis of phaeochromocytoma. Hypertension 1991; 17: 733–741.
Witteles RM, Kaplan EL, Roizen MF . Sensitivity of diagnostic and localization tests for phaeochromocytoma in clinical practice. Arch Intern Med 2000; 160: 2957–2963.
Messerli FH, Frohlich ED . High blood pressure. A side effect of drugs, poisons, and food. Arch Intern Med 1979; 139: 682–687.
Proye C, Fossati P, Fontaine P, Lefebre J, Decoulx M, Wemeau JL et al. Dopamine-secreting phaeochromocytoma: an unrecognised entity? Classification of phaeochromocytomas according to their type of secretion. Surgery 1986; 100: 1154–1161.
Eisenhofer G, Walther M, Keiser HR, Lenders JWM, Friberg P, Pacak K . Volume plasma metanephrines: a novel and cost-effective test for pheochromocytoma. Braz J Med Biol Res 2000; 33 (10): 1157–1169.
Goldstein DS, Eisenhofer G, Flynn JA, Wand G, Pacak K . Diagnosis and localization of phaeochromocytoma. Hypertension 2004; 43: 907–910.
Sawka AM, Jaeschke R, Singh RJ, Young Jr WF . A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-h urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88: 553–558.
Eisenhofer G, Lenders JWM, Goldstein DS, Mannelli M, Csako G, Walther MM et al. Phaeochromocytoma catecholamine phenotypes and prediction of tumour size and location by use of plasma free metanephrines. Clin Chem 2005; 51 (4): 735–744.
Mannelli M, Ianni L, Cilotti A, Conti A . Phaeochromocytoma in Italy: a multicentre retrospective study. Eur J Endocrinol 1999; 141 (6): 619–624.
Elliot WJ, Murphy MB . Reduced specificity of the clonidine suppression test in patients with normal plasma catecholamines levels. Am J Med 1988; 84: 419–424.
Acknowledgements
We are grateful to Sister D Saunderson and the nursing staff of Ward 7D, Royal Victoria Hospital for their expertise. During the course of this analysis, Dr Claire McHenry, Research Fellow, was in receipt of funding from the R&D office, Northern Ireland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
McHenry, C., Hunter, S., McCormick, M. et al. Evaluation of the clonidine suppression test in the diagnosis of phaeochromocytoma. J Hum Hypertens 25, 451–456 (2011). https://doi.org/10.1038/jhh.2010.78
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2010.78